Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Silverback Therapeutics (Nasdaq: SBTX), a clinical-stage biopharmaceutical firm, announced its participation in the 2021 Wedbush PacGrow Healthcare Conference on August 10-11, 2021. CEO Laura Shawver will join the 'Heavenly (anti)Bodies' panel on August 10 at 1:10 p.m. ET. The company focuses on developing targeted therapeutics for cancer and chronic viral infections using its proprietary ImmunoTAC platform, which aims to enhance treatment effectiveness by directing specific agents to disease sites. For more details, visit silverbacktx.com.

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the 2021 Wedbush PacGrow Healthcare Conference from August 10-11, 2021.

Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, will participate in the “Heavenly (anti)Bodies” panel on Tuesday, August 10, 2021 at 1:10 p.m. ET (10:10 a.m. PT). Members of the Silverback management team will also host investor meetings during the conference.

About Silverback Therapeutics

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005026/en/

FAQ

When is Silverback Therapeutics participating in the 2021 Wedbush PacGrow Healthcare Conference?

Silverback Therapeutics will participate in the 2021 Wedbush PacGrow Healthcare Conference on August 10-11, 2021.

Who from Silverback Therapeutics will speak at the conference?

CEO Laura Shawver will participate in the 'Heavenly (anti)Bodies' panel on August 10, 2021 at 1:10 p.m. ET.

What is Silverback Therapeutics focusing on at the conference?

Silverback Therapeutics is focusing on discussing its proprietary ImmunoTAC technology platform and its applications in treating cancer and chronic viral infections.

What is Silverback Therapeutics' ImmunoTAC technology?

ImmunoTAC is a technology platform used by Silverback to develop targeted therapies that deliver payloads to specific disease sites, aimed at treating cancer and serious diseases.

Where is Silverback Therapeutics located?

Silverback Therapeutics is located in Seattle, Washington.